Roche: Slow And Steady Wins The Race
This article was originally published in The Pink Sheet Daily
The firm got off to a solid start in 2016, which should see its biggest launches in years, but its core strength remains executing long-term management of its key franchises.
You may also be interested in...
Genentech’s Alecensa Joins The ALK Inhibitor Market
Alectinib will launch within two weeks for second-line ALK-positive non-small lung cancer at the price of $12,500 per month.
Roche’s Ocrelizumab Poised To Seize Primary Progressive MS Opportunity
Roche plans to file the selective CD20 antibody in 2016 after releasing positive Phase III data at ECTRIMS in both relapsing-remitting and primary progressive multiple sclerosis, a debilitating form of the disease for which there are no approved drugs.
Eylea, Avastin Both Get A Boost From NIH Comparative Study In DME
The first head-to-head comparison of Eylea, Avastin and Lucentis in diabetic macular edema shows a superior benefit for Eylea in patients with more advanced vision loss and that Avastin is as effective as the other two drugs in other patients.